Genprex Inc., a clinical-stage gene therapy company, recently announced the presentation of positive preclinical data for its diabetes gene therapy drug candidate, GPX-002. The findings were shared at the 2025 American Diabetes Association 85th Scientific Sessions held in Chicago. The research, conducted in collaboration with Genprex's partners, explores a novel non-viral lipid nanoparticle delivery system that may allow for repeat dosing, a potential advantage over traditional AAV delivery methods. The study, which involved testing nine different lipid nanoparticles for transfection efficiency in isolated mouse Islets of Langerhans, showed promising results, particularly with LNPs made using ALX-184. These findings represent Genprex's ongoing effort to optimize gene therapy delivery systems for diabetes treatment. The full presentation details and poster are available on Genprex's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.